APPENDIX I:

CLAIM AMENDMENTS:

Amend Claims 11, 12, 14, 15 and 26 to 29 as indicated in the following listing of the claims:

1. - 10. (*canceled*)

11. (*currently amended*) A method for the enzymatic production of terminally or subterminally hydroxylated fatty acids, which comprises

a) converting a fatty acid selected from terminally saturated, branched or unbranched fatty acids with 8 to 30 carbon atoms or a fatty acid derivative thereof, selected from C_1-C_4 alkyl esters, amides and anhydrides, in the presence of an electron donor system, a cytochrome P450 monooxygenase and oxygen wherein said electron donor system comprises an inorganic, non-electrode bound source of electrons and a mediator which is able to transfer electrons from the source of electrons to the enzyme, wherein said enzyme is a cytochrome P450-containing mono-oxygenase (E.C. 1.14) of the families CYP4, CYP52, CYP102, and wherein the source of electrons is a metal in powder form with a lower standard normal potential than the mediator; and

b) isolating the hydroxylated product(s).

12. (*currently amended*) A method as claimed in claim 11, ~~wherein the~~ in which an ω-hydroxylatable fatty acid ~~derivative is~~ selected from terminally saturated, branched ~~or~~ and unbranched C_{10}-C_{30} fatty acids is employed in (a).

13. (*canceled*)

14. (*currently amended*) A method as claimed in claim 11, wherein the cytochrome P450 mono oxygenase has a modification in the amino acid sequence of SEQ ID NO:35, which modification consists of a single mutation wherein F87 is replaced by A or V, L188 is replaced by K, V26 is replaced by T, R47 is replaced by F, or V26 is replaced by T.

15. (*currently amended*) A method as claimed in claim 11, wherein the cytochrome P450 mono oxygenase has a modification in the amino acid sequence of SEQ ID NO:35, which modification consists of a mutation wherein F87 is replaced by A or V, and one further modi-

fication wherein L188 is replaced by K, A74 is replaced by G, R47 is replaced by F and V26 is replaced by T.

16. (*previously presented*) A method as claimed in claim 26, wherein the electron donor system is zinc/Co(III) sepulcrate.

17. (*previously presented*) A method as claimed in claim 11, wherein at least stage a) is carried out in the presence of chloride ions.

18. (*previously presented*) A method as claimed in claim 11, wherein at least stage a) is carried out in the presence of a hydrogen peroxide-cleaving enzyme.

19. - 22. (*canceled*)

23. (*previously presented*) A method as claimed in claim 11, wherein the mediator has a standard normal potential in the region of less than about -0.4 V.

24. (*previously presented*) A method as claimed in claim 11, wherein the mediator is selected from cobalt(III) sepulcrate, methylviologen, neutral red, riboflavin, ruthenium triacetate, FMN and FAD.

25. (*previously presented*) A method as claimed in claim 11, wherein the source of electrons is metallic zinc.

26. (*currently amended*) A method as claimed in claim 11, wherein the source of electrons is selected from the systems:

- Zn/cobalt(III) sepulcrate and
- Zn/neutral red.

27. (*currently amended*) A method as claimed in claim 12, ~~wherein the~~ in which an ω-hydroxylatable fatty acid ~~derivative is~~ selected from terminally saturated, branched ~~or~~ and unbranched C_{12}-C_{30} fatty acids is employed in (a).

28. (*currently amended*) A method as claimed in claim 12, ~~wherein the~~ in which an ω-hydroxylatable fatty acid ~~derivative is~~ selected from terminally saturated, branched ~~or~~ and unbranched C_{12}-C_{25} fatty acids is employed in (a).

29. (*currently amended*) A method as claimed in claim 12, ~~wherein the~~ in which an ω-hydroxylatable fatty acid ~~derivative is~~ selected from terminally saturated, branched ~~or~~ and unbranched C_{12}-C_{20} fatty acids is employed in (a).

30. (*previously presented*) A method as claimed in claim 11, wherein the cytochrome P450 mono oxygenase is a mutant, which is obtained by amino acid substitution in at least one of positions 26, 47, 72, 74, 87, 188 and 354, of the wild-type enzyme (SEQ ID NO: 35).